Test Price
1,100 AED✅ Home Collection Available
IMD Panel Quantitative Blood Test (Inborn Errors of Metabolism) in UAE | 1100 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection for infant heel-prick samples, available daily from 8 AM to 11 PM.
Clinical Guidance: Telephonic Post-Test Clinical Guidance for precise result interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview: The IMD Panel Quantitative Blood Test is a comprehensive, next‑generation screening tool that quantifies multiple inborn errors of metabolism using tandem mass spectrometry, enabling early detection of over 30 metabolic disorders from a single heel-prick dried blood spot. Designed for newborns, children, and at‑risk adults, this test delivers rapid, high‑precision results in full compliance with DHA and MOHAP regulations.
Test Overview & Methodology
This quantitative metabolic screen employs tandem mass spectrometry (LC‑MS/MS) to measure amino acids, acylcarnitines, and organic acids from three dried blood spots on filter paper. The test identifies over 30 metabolic disorders including phenylketonuria, maple syrup urine disease, medium‑chain acyl‑CoA dehydrogenase deficiency, and other amino acidopathies, organic acidurias, and fatty acid oxidation disorders.
| Feature | Our IMD Panel (Precision) | Closest Alternative (Standard NBS) |
|---|---|---|
| Analytical Method | Tandem Mass Spectrometry (LC‑MS/MS) – quantitative | Immunoassay / Guthrie bacterial assay – semi‑quantitative |
| Disorder Coverage | Over 30 metabolic disorders (amino‑acid, organic acid, fatty‑acid oxidation) | Typically 2–6 core conditions |
| Turnaround Time | Next‑day reporting (sample Mon/Wed/Fri by 9 am) | 3–7 days |
| Sample Type | 3 dried blood spots on filter paper – minimal pain, infant‑friendly | Larger heel‑prick or venous sample |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “Genetic and metabolic testing in early life offers an extraordinary window into a child’s future health, yet results must always be interpreted within the full clinical context. A single metabolite level does not constitute a diagnosis—it is a biochemical clue that demands expert correlation with physical findings and family history. Our multidisciplinary team ensures that every family receives not just numerical data, but actionable, compassionate guidance from sample collection through long‑term follow‑up.”
Advisory & Safety Guidance
Medication & Dietary Management Advisory
Do not discontinue or adjust any prescribed medication, dietary formula, or metabolic supplementation regimen without consulting your supervising physician. Inborn errors of metabolism often require precise dietary control and medication timing; any unmonitored change may precipitate acute metabolic decompensation. Always maintain a current medication list for the attending phlebotomist.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients in acute metabolic decompensation (e.g., severe hypoglycaemia, hyperammonaemia) require stabilisation before elective blood spot collection.
- Exclusion: Inability to obtain an adequate heel-prick sample due to severe oedema or circulatory compromise; alternative venous sampling must be arranged by the referring physician.
- Red Flag – seek immediate emergency care (999): Sudden lethargy, intractable vomiting, seizures, or respiratory distress in a patient awaiting or following metabolic testing.
Patient FAQ & Clinical Guidance
1. What does the IMD Panel Quantitative Blood screen for?
This quantitative metabolic screen uses tandem mass spectrometry to measure over 30 inborn errors of metabolism, including amino acidopathies, organic acidurias, and fatty acid oxidation disorders, from a single dried blood spot. The panel provides precise concentration values for each metabolite, enabling your physician to differentiate between benign variants and clinically significant disorders that require immediate intervention.
2. How is the sample collected and what do I need to prepare?
A trained paediatric phlebotomist collects three tiny drops of heel-prick blood onto filter paper during a comfortable home visit. You should provide the infant’s clinical history, current medication list, and feeding regimen (breast milk, formula type, and any supplements) prior to collection. No fasting is required for routine newborn screening; however, the sample should ideally be collected 24–48 hours after birth for optimal sensitivity.
3. When will I receive the results and what is the total cost?
Samples collected Monday, Wednesday, or Friday before 9 am deliver a detailed digital report the very next day. The complete home collection and testing package is priced at 1100 AED, inclusive of the clinical report and telephonic post‑test guidance. Results are delivered securely via encrypted digital portal or email, with a follow‑up consultation available to discuss findings with our genetics team.
4. Can this test be performed after newborn screening samples have already been collected?
Yes. This quantitative panel is suitable for confirmatory testing following an abnormal newborn screen, for older infants and children with developmental delay or metabolic symptoms, and for at‑risk adults with a family history of metabolic disorders. The quantitative nature of LC‑MS/MS allows precise monitoring of known metabolic conditions over time.
5. Will my insurance cover the cost of this test?
Coverage depends on your specific policy and the clinical indication provided by your referring physician. Our team can verify direct billing arrangements via WhatsApp at +971 54 548 8731. For self‑pay patients, the all‑inclusive fee of 1100 AED covers collection, analysis, and clinical interpretation.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Confidentiality: DNA Labs UAE operates under the strict data protection framework of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient records, test results, and personal data are encrypted in transit and at rest, with access restricted to authorised clinical personnel only.
Clinical Safety & Patient Consent: All clinical procedures, including sample collection and reporting, are conducted in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Informed consent is obtained prior to any diagnostic procedure, and patients retain the right to access, correct, or request deletion of their personal data in compliance with PDPL Article 9.
Accreditations: Our laboratory holds ISO 9001:2015 certification and adheres to DHA standards for diagnostic testing and quality management. The IMD Panel Quantitative Blood Test is performed under DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | IMD Panel Quantitative Blood Test (Inborn Errors of Metabolism) |
| Price (AED) | 1100 |
| Turnaround Time | Next-day reporting (samples accepted Mon/Wed/Fri before 9 AM) |
| Sample Type / Matrix | Dried Blood Spot (heel-prick on filter paper) |
| Methodology Used | Tandem Mass Spectrometry (LC-MS/MS) – Quantitative |
| ICD-10-CM Code | Z13.228 |
| LOINC Code | 65721-0 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians